Description

Research is focused on imaging and endovascular treatment of neurovascular diseases including acute ischemic and hemorhagic stroke.
A research project on Computational Fluid Dynamics of intracranial aneurysms was started in collaboration with the departments of medical physics, neurosurgery, anesthesiology of the AMC and the University of Twente. The aim of this project is to improve rupture risk assessment of aneurysms by using advanced imaging techniques, including 7T MRI. In 2010 a multicenter randomized clinical trial was started inclose cooperation with the departments of neurology and radiology of the AMC, Erasmus MC and MUMC, evaluating the safety and effectiveness of endovascular treatment of acute ischemic stroke (MRCLEAN: www.mrclean-trial.org) funded by the Dutch Heart Foundation. The trial was completed in July 2014 and showed that in patientes with acute ischemic stroke due to a large vessel occlusion intraarterial treatment leads to a siginificant higher rate of functional independence. The results were in published in the NEJM (January,1, 2015) and had a major impact of the treatment of patients with acute ischemic stroke worldwide. The long term follow-up and cost-effectiveness of this treatment is assessed in a ZonMW funded project. Advanced image analysis of ischemic stroke is performed
inclose collaboration with the Department of Biomedical Engineering and Physics (AMC) and the department of interventional neuroradiology, Texas Stroke Institute, Dallas, USA. In 2016 a large grant was acquired from the Dutch Heart Foundation for CONTRAST (COnsortium for New TReatments of Acute STroke) in collaboration with Erasmus MC and 17 other hospitals in the Netherlands with additional support from industry (unrestricetd grants) and Dutch Brain Foundation (15.000 keu). The main aims of CONTRAST are 1. to improve the process of stroke care and achieve faster optimal stroke treatment for more patients; 2. to develop and test new treatments for a broad population of patients with ischemic stroke or ICH; and 3. to broaden the indication for IAT and increase the benefit of this treatment. These aims will be reached through a united effort of basic and clinical scientists. We will perform five large acute stroke trials to test novel treatment strategies, including 1. pre-hospital augmentation of collateral blood flow and blood pressure reduction; 2. antithrombotics to prevent microvascular occlusion after IAT; 3. immediate IAT without preceding thrombolysis; 4. IAT in the 6 to 12
hour time window; and 5. microsurgical hematoma evacuation and dexamethasone in patients with ICH. We aim to identify patients who will benefit from these interventions through advanced imaging. Novel stroke treatments with animal models will be developed, in combination with data from our clinical biobank. Mathematical modelling of data from the trials will optimize stroke care.


Theme: Neurological and Psychiatric Disorders
StatusActive
Effective start/end date1/07/07 → …

ID: 178938